mFOLFOXIRI 与 XELOX/SOX 作为局部晚期直肠癌新辅助化疗的回顾性比较。
Retrospective Comparison of mFOLFOXIRI With XELOX/SOX as Neoadjuvant Chemotherapy for Locally Advanced Rectal Cancer.
机构信息
Department of Gastroenterology, Osaka Medical College, Osaka, Japan.
Cancer Chemotherapy Center, Osaka Medical College Hospital, Osaka, Japan;
出版信息
In Vivo. 2021 Mar-Apr;35(2):977-985. doi: 10.21873/invivo.12340.
BACKGROUND/AIM: Neoadjuvant chemotherapy without radiation (NAC) shows favorable outcomes for locally advanced rectal cancer (LARC), however, the optimal regimen has not been determined yet. This study aimed to compare the efficacy and safety of oxaliplatin, irinotecan, folinic acid, and 5-fluorouracil (mFOLFOXIRI) with capecitabine/S-1 and oxaliplatin (XELOX/SOX) in rectal cancer patients.
PATIENTS AND METHODS
We retrospectively examined patients with LARC who received mFOLFOXIRI or XELOX/SOX as NAC.
RESULTS
Between January 2015 and July 2019, 49 patients received mFOLFOXIRI and 37 patients received XELOX/SOX. The pathological response rates (over two-thirds affected tumor area) were 36.7% and 40.5% in the mFOLFOXIRI and XELOX/SOX groups, respectively. Grade 3/4 neutropenia was experienced by 45.0% of the patients in the mFOLFOXIRI group and 8.0% in the XEOX/SOX group.
CONCLUSION
Although pathological responses were comparable between two groups, mFOLFOXIRI tended to be more toxic compared to XELOX/SOX as NAC for LARC.
背景/目的：新辅助化疗不联合放疗（NAC）显示出对局部晚期直肠癌（LARC）有利的结果，然而，尚未确定最佳方案。本研究旨在比较奥沙利铂、伊立替康、亚叶酸和 5-氟尿嘧啶（mFOLFOXIRI）与卡培他滨/S-1 和奥沙利铂（XELOX/SOX）在直肠癌患者中的疗效和安全性。
患者和方法
我们回顾性地检查了接受 mFOLFOXIRI 或 XELOX/SOX 作为 NAC 的 LARC 患者。
结果
2015 年 1 月至 2019 年 7 月，49 例患者接受 mFOLFOXIRI 治疗，37 例患者接受 XELOX/SOX 治疗。mFOLFOXIRI 和 XELOX/SOX 组的病理缓解率（超过三分之二受影响的肿瘤面积）分别为 36.7%和 40.5%。mFOLFOXIRI 组有 45.0%的患者发生 3/4 级中性粒细胞减少，而 XELOX/SOX 组有 8.0%的患者发生中性粒细胞减少。
结论
尽管两组的病理缓解率相当，但与 XELOX/SOX 相比，mFOLFOXIRI 作为 NAC 治疗 LARC 可能更具毒性。
Zotero 插件